NeoVista Update 5: CABERNET Study Did Not Meet Primary Endpoint at Two Years

In an unexpected outcome, Dr. Pravin Dugel presented the 2-year results of the CABERNET study, evaluating the use of NeoVista’s VIDION ANV epimacular brachytherapy device at the Bascom Palmer Eye Institute's (BPEI) Angiogenesis, Exudation, and Degeneration 2012 Meeting in Miami on Februay 4th.

As described in the following extensive writeup from Retina Today, the Phase 3, multicenter, prospective, randomized study did not achieve its primary endpoint after two years.

As I have previously written (see Update 4), the device has been commercialized extensively in Europe and the company was hoping that promising results in the CABERNET study would (Read more...)

Full Story →